Targeting NMNAT1 to Axons and Synapses Transforms Its Neuroprotective Potency<i>In Vivo</i>Elisabetta Babetto, Michael P. Coleman|Journal of Neuroscience|2010Cited by 123
Alzheimer’s Disease: Etiology, Neuropathology and PathogenesisOlivia Sheppard, Michael P. Coleman|Exon Publications eBooks|2020Cited by 93
Enrichment of SARM1 alleles encoding variants with constitutively hyperactive NADase in patients with ALS and other motor nerve disordersJonathan Gilley, Michael P. Coleman|eLife|2021Cited by 82
NMNAT2 is a druggable target to drive neuronal NAD productionJames R. Tribble, Pete A. Williams, Carmine Varricchio et al.|Nature Communications|2024Cited by 36
Mitochondrial impairment activates the Wallerian pathway through depletion of NMNAT2 leading to SARM1-dependent axon degenerationAndrea Loreto, Michael P. Coleman|bioRxiv (Cold Spring Harbor Laboratory)|2019Cited by 10